Details about Iain M. Cockburn

Access statistics for papers by Iain M. Cockburn.

Last updated 2012-04-20. Update your information in the RePEc Author Service.

Short-id: pco166

Working Papers

2013

1. Price Indexes for Clinical Trial Research: A Feasibility Study
   NBER Working Papers, National Bureau of Economic Research, Inc

2012

2. Why are Some Regions More Innovative than Others? The Role of Firm Size Diversity
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)

2009

3. Not Invented Here? Innovation in Company Towns
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)
   See also Chapter (2010)
   Journal Article in Journal of Urban Economics (2010)
4. Patent thickets, licensing and innovative performance
   ZEW Discussion Papers, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research
   Also in ZEW Discussion Papers, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research (2008) View citations (1)
   See also Journal Article in Industrial and Corporate Change (2010)

2007

5. Patents and the Survival of Internet-related IPOs
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (19)
   See also Journal Article in Research Policy (2010)
6. Patents, Thickets, and the Financing of Early-Stage Firms: Evidence from the Software Industry
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (3)
   See also Chapter (2007)
   Journal Article in Journal of Economics & Management Strategy (2009)

2006

7. Entry and Patenting in the Software Industry
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (5)
   See also Journal Article in Management Science (2011)
8. Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (3)
   See also Journal Article in Annales d'Economie et de Statistique (2005)

2004

9. Faster, Smaller, Cheaper: An Hedonic Price Analysis of PDAs
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (3)
   See also Journal Article in Applied Economics (2008)

2003

10. Gone But Not Forgotten: Labor Flows, Knowledge Spillovers, and Enduring Social Capital
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (42)

2002

11. Are All Patent Examiners Equal? The Impact of Examiner Characteristics
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (13)
12. University Research, Industrial R&D, and the Anchor Tenant Hypothesis
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (4)

2000

13. Do Patents Matter?: Empirical Evidence after GATT
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (17)

1999

14. Balancing Incentives: The Tension Between Basic and Applied Research
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (17)
15. Public-Private Interaction and the Productivity of Pharmaceutical Research
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (17)
16. The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (16)

1998

17. Hedonic Analysis of Arthritis Drugs
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (8)
    See also Chapter (2001)

1997

18. Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)
    See also Chapter (1998)
    Journal Article in Forum for Health Economics & Policy (1998)

1996

19. Characteristics of Demand for Pharmaceutical Products: an Examination of four Cephalosporins
    Working papers, Massachusetts Institute of Technology (MIT), Department of Economics View citations (8)
    See also Journal Article in RAND Journal of Economics (1997)

1995

20. Generics and New Goods in Pharmaceutical Price Indexes
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (4)
    See also Journal Article in American Economic Review (1994)

1994

21. Measuring competence?: exploring firm effects in pharmaceutical research
    Working papers, Massachusetts Institute of Technology (MIT), Sloan School of Management View citations (123)
22. Racing to invest?: the dynamics of competition in ethical drug discovery
    Working papers, Massachusetts Institute of Technology (MIT), Sloan School of Management View citations (23)
    See also Journal Article in Journal of Economics & Management Strategy (1994)

1993

23. Racing or spilling?: the determinants of research productivity in ethical drug discovery
    Working papers, Massachusetts Institute of Technology (MIT), Sloan School of Management
24. Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (5)
25. Scale, scope and spillovers: the determinants of research productivity in ethical drug discovery
    Working papers, Massachusetts Institute of Technology (MIT), Sloan School of Management View citations (2)

1992

26. Market Conditions and Retirement of Physical Capital: Evidence fron Oil Tankers
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)

1987

27. Industry Effects and Appropriability Measures in the Stock Markets Valuation of R&D and Patents
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (21)
    See also Journal Article in American Economic Review (1988)

Undated

28. A Mixed Poisson Regression Model for Analysis of Patent Data
    Computing in Economics and Finance 1996, Society for Computational Economics
29. Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery
    Working Papers, Department of Economics, University of Lancaster View citations (43)
    See also Journal Article in RAND Journal of Economics (1996)

Journal Articles

2011

1. Diffusion of New Drugs in the Post-TRIPS Era
   International Journal of the Economics of Business, 2011, 18, (2), 203-224
2. Entry and Patenting in the Software Industry
   Management Science, 2011, 57, (5), 915-933 View citations (9)
   See also Working Paper (2006)

2010

3. Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy
   Capitalism and Society, 2010, 5, (1), 1 View citations (1)
4. Not Invented Here? Innovation in company towns
   Journal of Urban Economics, 2010, 67, (1), 78-89 View citations (8)
   See also Chapter (2010)
   Working Paper (2009)
5. Patent thickets, licensing and innovative performance
   Industrial and Corporate Change, 2010, 19, (3), 899-925 View citations (1)
   See also Working Paper (2009)
6. Patents and the survival of Internet-related IPOs
   Research Policy, 2010, 39, (2), 214-228 View citations (6)
   See also Working Paper (2007)

2009

7. Patents, Thickets and the Financing of Early-Stage Firms: Evidence from the Software Industry
   Journal of Economics & Management Strategy, 2009, 18, (3), 729-773 View citations (11)
   See also Chapter (2007)
   Working Paper (2007)

2008

8. Faster, smaller, cheaper: an hedonic price analysis of PDAs
   Applied Economics, 2008, 40, (22), 2839-2856 View citations (1)
   See also Working Paper (2004)

2005

9. Public & Private Spillovers: Location and the Productivity of Pharmaceutical Research
   Annales d'Economie et de Statistique, 2005, (79-80), 165-188
   See also Working Paper (2006)

2003

10. The anchor tenant hypothesis: exploring the role of large, local, R&D-intensive firms in regional innovation systems
    International Journal of Industrial Organization, 2003, 21, (9), 1227-1253 View citations (29)

2001

11. New Pills for Poor People? Empirical Evidence after GATT
    World Development, 2001, 29, (2), 265-289 View citations (21)
12. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research
    Journal of Health Economics, 2001, 20, (6), 1033-1057 View citations (16)

1998

13. Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery
    Journal of Industrial Economics, 1998, 46, (2), 157-82 View citations (107)
14. Analysis of Patent Data--A Mixed-Poisson-Regression-Model Approach
    Journal of Business & Economic Statistics, 1998, 16, (1), 27-41 View citations (19)
15. Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs
    Forum for Health Economics & Policy, 1998, 1, 3 View citations (2)
    See also Chapter (1998)
    Working Paper (1997)

1997

16. Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins
    RAND Journal of Economics, 1997, 28, (3), 426-446 View citations (45)
    See also Working Paper (1996)
17. Generics and New Goods in Pharmaceutical Price Indexes: Reply
    American Economic Review, 1997, 87, (4), 768

1996

18. Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery
    RAND Journal of Economics, 1996, 27, (1), 32-59 View citations (69)
    See also Working Paper

1995

19. Opportunity costs and entrepreneurial activity
    Journal of Business Venturing, 1995, 10, (2), 95-106 View citations (22)

1994

20. Generics and New Goods in Pharmaceutical Price Indexes
    American Economic Review, 1994, 84, (5), 1213-32 View citations (32)
    See also Working Paper (1995)
21. Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery
    Journal of Economics & Management Strategy, 1994, 3, (3), 481-519 View citations (35)
    See also Working Paper (1994)

1988

22. Industry Effects and Appropriability Measures in the Stock Market's Valuation of R&D and Patents
    American Economic Review, 1988, 78, (2), 419-23 View citations (47)
    See also Working Paper (1987)

Chapters

2011

1. Comment on "The Confederacy of Software Production: Field Experimental Evidence on Heterogeneous Developers, Tastes for Institutions and Effort"
   A chapter in The Rate and Direction of Inventive Activity Revisited, 2011, pp 502-505
2. Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Energy R&D
   A chapter in Accelerating Energy Innovation: Insights from Multiple Sectors, 2011, pp 113-157

2010

3. Not Invented Here? Innovation in Company Towns
   A chapter in Cities and Entrepreneurship, 2010 View citations (5)
   See also Working Paper (2009)
   Journal Article in Journal of Urban Economics (2010)
4. Public and Private Spillovers: Location and the Productivity of Pharmaceutical Research
   A chapter in Contributions in Memory of Zvi Griliches, 2010, pp 165-188 View citations (7)
5. The Global Location of Biopharmaceutical Knowledge Activity: New Findings, New Questions
   A chapter in Innovation Policy and the Economy, Volume 10, 2010, pp 129-157

2007

6. Is the Pharmaceutical Industry in a Productivity Crisis?
   A chapter in Innovation Policy and the Economy, Volume 7, 2007, pp 1-32
7. Patents, Thickets and the Financing of Eastly-Stage Firms; Evidence from the Software Industry
   A chapter in Entrepreneurship: Strategy and Structure, 2007
   See also Working Paper (2007)
   Journal Article in Journal of Economics & Management Strategy (2009)

2001

8. Hedonic Analysis of Arthritis Drugs
   A chapter in Medical Care Output and Productivity, 2001, pp 439-462 View citations (2)
   See also Working Paper (1998)
9. Publicly Funded Science and the Productivity of the Pharmaceutical Industry
   A chapter in Innovation Policy and the Economy, Volume 1, 2001, pp 1-34 View citations (9)

1998

10. Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs
    A chapter in Frontiers in Health Policy Research, volume 1, 1998, pp 33-76 View citations (2)
    See also Working Paper (1997)
    Journal Article in Forum for Health Economics & Policy (1998)